Hydroxycarbamide for anemia, sickle cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 May 2026: Trial started, NCT07708714
  2. 16 Jul 2026: Trial registered, NCT07708714

The trials

NCT07708714: Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

State
Under way
Phase
Phase 1 and Phase 2
People
250 planned
Started
13 May 2026
Primary completion
30 Nov 2030
Arms
Hydroxyurea: Original NOHARM Cohort, Hydroxyurea: New Comparator Cohort
Results
None posted
  1. 13 May 2026: Trial started
  2. 16 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Droxia, Hydrea, Hydroxyurea, Siklos, Xromi.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.